Gracell Biotechnologies Inc.

Ladies and gentlemen, thank you for standing by. Welcome to Gray Cell Biotechnology's second quarter 2022 conference call. At this time, all participants are in a listen-only mode. After opening remarks, we will open the call for your questions. Instructions for queuing up will be given at that time. I will now turn the conference call over to Dr. Kevin Scheer, CFO. Please go ahead.

Good morning. and welcome to GreenCell's second quarter 2022 corporate update conference call and webcast. With me today are GreenCell's founder and the chief executive officer, Dr. William Chow, and our chief medical officer, Dr. Wundi Li. We're excited to discuss our innovative technologies and the rich clinical pipeline of CAR T therapies on today's call. We're also looking forward to sharing with you our recent business development and upcoming objectives for 2022. After our formal remarks, we'll conduct a question and answer session. This morning, Grisel issued a press release announcing unaudited financial results for the quarter ended June 30, 2022. We encourage everyone to read this press release and would like to remind you that this call is being recorded for replay. Please note that for certain information discussed on the call today, including financial data, clinical data, and future plans of our programs, resource management will be making forward-looking statements. Actual results could differ materially from those stated or implied by those forward-looking statements as a result of various important factors and please refer to the risk factor section of our latest 20-year filing with SEC for a full disclosure of this risk and the factors. The conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, August 13, 2022. The result undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances of the date of this conference call, except as may be required by unpeopled security law. I will now turn the call over to Grisa CEO, Dr. William Tsang. William. Welcome everyone to our second quarter of 2022 Corporate Update Conference Call. I'm excited to begin today's call by highlighting our strengthened leadership team and then introducing our new CMO, Dr. Wendy Lee, to her first investor call as part of the Gray Cell Leadership Team. I will ask her to provide some background and a perspective on her recent move. I will then continue with a clinical development update as we made significant progress across a handful of our programs in recent months. Then I will hand the call over to our CFO, Dr. Kevin Shea. to discuss financial updates. After our prepared remarks, we will open the call to the questions. Let me start with our two recent executive appointments. Dr. Samuel Zhang was appointed Chief Business Officer in mid-July and is based in the U.S. He is responsible for strategic leadership of our global business development initiatives. He brings in Gracell over 20 years of industry experience across drug development stages and has a long history of managing strategic alliances and collaborations at both large pharmaceutical and small biotech companies. Dr. Wendy Lee joined Gracell as a chief medical officer on August 1st, and she is based in the U.S. Dr. Lee will oversee Gracell's clinical development activities, including the advancement of our rich pipeline of autologous and allogeneic product candidates across the fast car and the 2U car technology platforms. Before she joined us, she was a CMO at Exuma Biotech, where she provided strategic medical and clinical leadership for the advancement of its cell therapy pipeline in the U.S. and Asia. Dr. Lee brings in significant expertise on both clinical development and medical affairs and will be invaluable as we are on track to file the USR&D application for GC012F in relapsed refractory multiple myeloma, or RRMM, later this year. I will now turn the line over to Wendy.

Thank you, William. It is a tremendous honor to join Greenfield as its chief medical officer as the company continues to advance its pipeline on multiple fronts. I have several years of experience in the CAR-T field and also held oncology clinical development roles with increasing responsibilities over the past two decades, including leading early and late stage clinical trials for several therapeutic candidates for the treatment of hematological malignancy and the solid tumors. And overseeing more than 30 successful IMD findings, new drug applications and the biologics lessons applications in both the US and China. I believe a successful oncology therapy. needs to bring substantial clinical benefits to patients, especially those with high unmet medical needs. I recognize the significant differentiation and the vast potential of our pipeline based on the fast car and the two-year car platforms to fulfill those unmet medical needs. In past two weeks, I have been impressed by the caliber of the passionate Griselle team, both in China and in the U.S. I look forward to working closely with the entire clinical team as Griselle is on track to commence company-sponsored trials in relapse refractory multiple myeloma, or RRMM. For GC012F, in both the U.S. and China, pending the outcomes of the regulatory processes that are on the way. With that, I will turn the line back over to William. Thanks.